A Pilot Study of APG-157 With Bevacizumab for Patients With Recurrent High-Grade Glioma
This study is testing a new experimental drug called APG-157 to see if it helps treat recurrent high-grade glioma, which is a fast-growing type of brain tumor. Researchers want to see if adding this drug to standard care can help shrink tumors and improve the quality of life for patients.
You may be eligible if you are at least 19 years old and have a high-grade brain tumor that has returned or continued to grow after previous treatments like radiation and chemotherapy. You must also be generally healthy enough to participate, with no serious heart or blood vessel conditions.
Participants will continue to receive their standard care (bevacizumab) while adding the new drug, APG-157. You will take this study drug daily by letting two medicated lozenges dissolve in your mouth at each mealtime, for a total of six lozenges per day.
The study is currently recruiting patients at medical centers in Rochester, Minnesota, and Omaha, Nebraska. Please check with your doctor to see if you meet the specific medical requirements to join.
- 1The study combines a new drug with your existing standard brain cancer treatment.
- 2APG-157 is easy to take because it dissolves in your mouth like a lozenge.
- 3Researchers are closely monitoring how the tumor responds to treatment and how you feel throughout the process.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.